Yeztugo (lenacapavir) 300 mg once-weekly oral
Gilead Sciences (GILD)
Decision dateFeb 2, 2027
79 days away
Marketer take
Would add a weekly oral option to an existing PrEP brand, giving HIV prevention marketers a new dosing-choice message.
- Sponsor company
- Gilead Sciences (GILD)
- Indication
- HIV pre-exposure prophylaxis (sNDA)
- Therapeutic area
- Infectious disease
- Event
- PDUFA target action date
- Date
- Feb 2, 2027
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?